Research and Markets: U.S. Diabetes Drug Delivery - Physician Perspective

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/b6d9f6/u_s_diabetes_drug) has announced the addition of Frost & Sullivan's new report "U.S. Diabetes Drug Delivery - Physician Perspective" to their offering.

This study encompasses feedback provided by U.S. physicians who treat diabetes on aspects of drug delivery and drug treatment for diabetes, enabling interested stakeholders to gain insight into current and future trends. Analysis includes issues such as awareness, usage, preferences, influencing criteria, patient compliance, desired delivery types to be made available, as well as feedback on the role the device plays in the prescribing decision for a drug. The corresponding patient deliverable is titled: 2008 U.S. Diabetes Drug Delivery: Patient Perspective.

Solution/Outcome

For the full project, all major drug delivery technology categories were assessed. Data was presented for the general objective point questions as well as analysis by disease area. In addition, patient feedback about awareness, usage and desired changes was obtained for Exubera, Byetta, Enbrel, Humira, and Voltaren Gel. Also, for device driven delivery - autoinjector technology usage and willingness for adoption is assessed by patients, as well as other vital feedback on the role the device plays in the overall drug product for both physicians and patients. Proprietary work was analyzed and presented for the partner client assessing physician prescribing behavior and preferences specific to their needs through added proprietary questions in the questionnaire.

The data and information from this project, first made available in January 2008, has now been reanalyzed in full by major disease category, recut and made available as shorter deliverables by disease and respondent type (physician, patient) for our subscription clients.

Research Background 2010 Analysis

  • The physician information in this deliverable is from doctors who stated they actively treat and prescribe for diabetes, with questions framed for them to consider responses within the context of the treatment of diabetes.
  • Questions posed to physicians are at the bottom of each analysis slide.
  • The corresponding patient deliverable is titled: "2008 U.S. Diabetes Drug Delivery: Patient Perspective" (N7C0).

The study utilized Frost & Sullivan's web-based capability. A structured questionnaire with the appropriate metrics was set-up in web format (GMI-MR software). Appropriate screening questions and quota controls were provided to ensure that only qualified respondents participate in the survey.

Reporting Notes

Data resulting from sample sizes less than 50, should be considered directional, not actionable. Some charts may not add to 100.0% due to rounding.

Key Topics Covered:

U.S. Diabetes Drug Delivery - Physician Perspective

  • Research Background - Objectives - Method Details - Demographic Profile
  • Executive Summary
  • Overview of Awareness - Usage - Preferences
  • General Criteria and Perceptions that Influence Drug Delivery Type Preference
  • Profile of Patient Compliance and Administering Persons

For more information visit http://www.researchandmarkets.com/research/b6d9f6/u_s_diabetes_drug



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   Europe  Ireland

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.